Morinda officinalis How. - A comprehensive review of traditional uses, phytochemistry and pharmacology

J Ethnopharmacol. 2018 Mar 1:213:230-255. doi: 10.1016/j.jep.2017.10.028. Epub 2017 Nov 7.

Abstract

Ethnopharmacological relevance: The medicinal plant Morinda officinalisHow. (MO) and its root have long been used in traditional medicines in China and northeast Asia as tonics for nourishing the kidney, strengthening the bone and enhancing immunofunction in the treatment of impotence, osteoporosis, depression and inflammatory diseases such as rheumatoid arthritis and dermatitis.

Aim of the review: This review aims to sum up updated and comprehensive information about traditional usage, phytochemistry, pharmacology and toxicology of MO and provide insights into potential opportunities for future research and development of this plant.

Methods: A bibliographic investigation was performed by analyzing the information available on MO in the internationally accepted scientific databases including Pubmed, Scopus and Web of Science, SciFinder, Google Scholar, Yahoo, Ph.D. and M.Sc. dissertations in Chinese. Information was also obtained from some local and foreign books on ethnobotany and ethnomedicines.

Results: The literature supported the ethnomedicinal uses of MO as recorded in China for various purposes. The ethnomedical uses of MO have been recorded in many regions of China. More than 100 chemical compounds have been isolated from this plant, and the major constituents have been found to be polysaccharides, oligosaccharides, anthraquinones and iridoid glycosides. Crude extracts and pure compounds of this plant are used as effective agents in the treatment of depression, osteoporosis, fatigue, rheumatoid arthritis, and infertility due to their anti-depressant, anti-osteoporosis, pro-fertility, anti-radiation, anti-Alzheimer disease, anti-rheumatoid, anti-fatigue, anti-aging, cardiovascularprotective, anti-oxidation, immune-regulatory, and anti-inflammatory activities. Pharmacokinetic studies have demonstrated that the main components of MO including monotropein and deacetyl asperulosidic acid are distributed in various organs and tissues. The investigation on acute toxicity and genotoxicity indicated that MO is nontoxic. There have no reports on significant adverse effect at a normal dose in clinical application, but MO at dose of more than 1000mg/kg may cause irritability, insomnia and unpleasant sensations in individual cases.

Conclusion: MO has emerged as a good source of traditional medicines. Some uses of this plant in traditional medicines have been validated by pharmacological investigations. However, the molecular mechanism, structure-activity relationship, and potential synergistic and antagonistic effects of its multi-components such as polysaccharides, oligosaccharides, anthraquinones and iridoid glycosides need to be further elucidated, and the structural feature of polysaccharides also need to be further clarified. Sophisticated analytical technologies should be developed to comprehensively evaluate the quality of MO based on HPLC-fingerprint and content determination of the active constituents, knowing that these investigations will help further utilize this plant.

Keywords: (Z,Z)-9,12-octadecadienoic acid (PubChem CID:5280450); 1, 3-dihydroxy-2-methoxyanthraquinone (PubChemCID:14189688); 1-hexanol (PubChem CID:8103); 1-hydroxy-2-methyl anthraquinone (PubChemCID:160817); 1-hydroxy-anthraquinone (PubChemCID:8512); 1-kestose (PubChemCID: 440080); 2-hydroxy-1-methoxy-anthraquinone (PubChemCID:80309); 2-hydroxy-3-hydroxymethy-lanthraquinone (PubChem CID:44445519); 2-hydroxy-3-hydroxymethylanthraquinone (PubChemCID:44445519); 2-methoxyanthraquinone (PubChemCID:18646); 3-methyl-benzaldehyde (PubChem CID:12105); Alizarin-2-Methyl ether (PubChemCID:23669622); Ar-Curcumene (PubChem CID:92139); Asperuloside (PubChemCID:84298); Asperuloside tetraacetate (PubChemCID:443336); Asperulosidic acid (PubChemCID: 11968867); Benzeneacetaldehyde (PubChem CID:998); Bicyclo[4,2,0]octa-1,3,5-trien-7-O (PubChem CID:354193); Daucosterol (PubChem CID:5742590); Deacetyl asperulosidic acid (PubChemCID: 12315349); Digiferruginol (PubChemCID:32209); Fumaric acid (PubChemCID:444972); Hexasaccharide (PubChemCID: 3082034) Heptasaccharide (PubChem CID: 44630346); Inulopentaose (PubChemCID:101110146); Inulotetraose (PubChem CID: 101708615); Inulotriose (PubChemCID: 101708615); L-Camphor (PubChem CID:230921); L-borneol (PubChem CID:10049); Lucidin-ѡ-Ethyl ether (PubChem CID:28578); Mannose (PubChemCID:18950); Monotropein (PubChemCID:73466); Morinda officinalis How.; Morindolide (PubChemCID:10397184); Morofficinaloside (PubChemCID:10453987); N-Nonanal (PubChem CID:31289); N-hexadecanoic acid (PubChem CID:985); Nystose (PubChemCID:166775); Pentadecanoic acid (PubChem CID:13849); Pharmacology; Physcion (PubChemCID: 10639); Phytochemistry; Rubiadin (PubChemCID: 124062); Rubiadin-1-Methyl ether (PubChemCID:96191); Scopoletin (PubChem CID:5280460); Stigmasterol (PubChem CID: 5280394); Succinic acid (PubChemCID:1110); Sucrose (PubChemCID: 5988); Tectoquinone (PubChemCID:6773); Traditional uses; Trisaecharide (PubChemCID: 10206531); α-zingiberene (PubChem CID:92776); β-bisabolene (PubChem CID:10104370); β-sesquiphelandrene (PubChem CID:12315492); β-sitosterol (PubChemCID: 222284).

Publication types

  • Review

MeSH terms

  • Animals
  • Drugs, Chinese Herbal / adverse effects
  • Drugs, Chinese Herbal / chemistry*
  • Drugs, Chinese Herbal / therapeutic use*
  • Drugs, Chinese Herbal / toxicity
  • Ethnopharmacology
  • Humans
  • Morinda / adverse effects
  • Morinda / chemistry*
  • Morinda / toxicity
  • Phytotherapy*
  • Plant Extracts / adverse effects
  • Plant Extracts / chemistry
  • Plant Extracts / therapeutic use
  • Plant Extracts / toxicity

Substances

  • Drugs, Chinese Herbal
  • Plant Extracts